USE OF COMPLEMENT PATHWAY INHIBITOR COMPOUNDS TO MITIGATE ADOPTIVE T-CELL THERAPY ASSOCIATED ADVERSE IMMUNE RESPONSES

摘要

This invention provides methods for treating adoptive T-cell therapy-associated adverse inflammatory responses, for example, cytokine release syndrome and tumor lysis syndrome, using complement pathway inhibitor compounds.